Tag Archives: NASDAQ:CBAY

H.C. Wainwright Remains a Hold on CymaBay Therapeutics (CBAY)

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on CymaBay Therapeutics (CBAY – Research Report). The company’s shares closed last Monday at $1.86, close to its 52-week low of $1.29. According to TipRanks.com, Arce

CymaBay Therapeutics (CBAY) Gets a Buy Rating from Evercore ISI

In a report issued on November 22, Joshua Schimmer from Evercore ISI maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $12.00. The company’s shares closed last Monday at $5.55, close to its

Evercore ISI Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report) yesterday and set a price target of $15. The company’s shares closed last Monday at $5.95, close to its 52-week low of $4.82. According

CymaBay Therapeutics (CBAY) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report) today and set a price target of $12. The company’s shares opened today at $6.52. Arce noted: “916-3963, Rating POS Risk-adj value Full value

CymaBay Therapeutics (CBAY) Gets a Hold Rating from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR maintained a Hold rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $11. The company’s shares opened today at $12.60. Mamtani wrote: “Therapeutics, Inc. (CBAY-Neutral, $11

Oppenheimer Maintains a Buy Rating on CymaBay Therapeutics (CBAY)

Oppenheimer analyst Jay Olson maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report) today and set a price target of $18. The company’s shares closed yesterday at $9.77. Olson commented: “Seladelpar (PPARδ agonist) received Breakthrough Therapy Designation (BTD)